Gofen & Glossberg LLC IL Has $17.42 Million Holdings in Danaher Co. (DHR)
Gofen & Glossberg LLC IL raised its stake in Danaher Co. (NYSE:DHR) by 2.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 203,071 shares of the conglomerate’s stock after purchasing an additional 4,383 shares during the period. Gofen & Glossberg LLC IL’s holdings in Danaher were worth $17,419,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently bought and sold shares of the company. ETRADE Capital Management LLC raised its position in Danaher by 5.1% in the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after purchasing an additional 917 shares in the last quarter. Honeywell International Inc. acquired a new stake in Danaher in the 2nd quarter valued at about $25,317,000. Roundview Capital LLC raised its position in Danaher by 2.0% in the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after purchasing an additional 502 shares in the last quarter. Eastern Bank increased its holdings in shares of Danaher by 4,291.1% in the 2nd quarter. Eastern Bank now owns 128,001 shares of the conglomerate’s stock valued at $10,802,000 after acquiring an additional 125,086 shares during the last quarter. Finally, Perkins Coie Trust Co increased its holdings in shares of Danaher by 2.0% in the 2nd quarter. Perkins Coie Trust Co now owns 29,431 shares of the conglomerate’s stock valued at $2,484,000 after acquiring an additional 586 shares during the last quarter. 76.32% of the stock is currently owned by institutional investors.
A number of research analysts have recently commented on DHR shares. Morgan Stanley increased their price objective on Danaher from $95.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 20th. Credit Suisse Group increased their price objective on Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 price objective on the stock in a report on Thursday, October 5th. Goldman Sachs Group reiterated a “neutral” rating and issued a $83.00 price objective on shares of Danaher in a report on Tuesday, September 26th. Finally, Robert W. Baird increased their price objective on Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, October 20th. One analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $93.31.
Danaher Co. (NYSE DHR) opened at $94.15 on Thursday. The stock has a market capitalization of $65,164.29, a P/E ratio of 24.08, a P/E/G ratio of 2.23 and a beta of 1.02. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. Danaher Co. has a 12 month low of $77.66 and a 12 month high of $94.82.
Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05. The firm had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.87 EPS. analysts expect that Danaher Co. will post 3.99 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be paid a dividend of $0.14 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.59%. Danaher’s dividend payout ratio is presently 16.52%.
In related news, SVP Daniel Raskas sold 37,870 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total value of $11,671,620.96. Following the transaction, the chief executive officer now owns 271,737 shares in the company, valued at approximately $25,173,715.68. The disclosure for this sale can be found here. Insiders have sold a total of 273,810 shares of company stock worth $25,218,813 in the last 90 days. 12.20% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Gofen & Glossberg LLC IL Has $17.42 Million Holdings in Danaher Co. (DHR)” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/gofen-glossberg-llc-il-has-17-42-million-holdings-in-danaher-co-dhr/1763154.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with Analyst Ratings Network's FREE daily email newsletter.